Trial Profile
A Double-Blind, Placebo-Controlled, Randomized, Multiple Ascending Dose Study to Investigate the Safety, Tolerability and Pharmacokinetics of JNJ-39393406 in Healthy Subjects
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 03 Mar 2014
Price :
$35
*
At a glance
- Drugs JNJ 39393406 (Primary)
- Indications Alzheimer's disease; Cognition disorders
- Focus Adverse reactions; Pharmacokinetics
- Sponsors Janssen Research & Development
- 09 Jan 2014 New trial record